Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of FCN-159 in adolescents and adults with extracranial arteriovenous malformations
CTR20244693Phase 2Active
- Sponsor
- Fosun Pharma
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib in extracranial arteriovenous malformation (EAVM), capillary malformation-arteriovenous malformation syndrome (CM-AVM), sponsored by Fosun Pharma. Started Feb 2025; status: active.
02
Drugs
luvometinib
03
Conditions
extracranial arteriovenous malformation (EAVM)capillary malformation-arteriovenous malformation syndrome (CM-AVM)
Beyond the preview
Go deeper on CTR20244693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244693.